Genomic Health (Nasdaq: GHDX) announced strongly positive results from an additional independent clinical validation study of the Oncotype DX® prostate ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE